Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.
From Bio-Rad LaboratoriesMay 1 2024 Bio-Rad Laboratories, Inc. , a global leader in life science research and clinical diagnostics products, today announced the launch of three new StarBright™ Red Dyes—StarBright Red 715, 775, and 815—and an expansion of its StarBright Violet Dye series with 29 additional highly validated antibodies conjugated to StarBright Violet 570, 515, 440, 670, 790, and 475 Dyes.
Bio-Rad’s range of StarBright Dyes, proprietary fluorescent nanoparticles conjugated to flow-validated antibodies against key immunological targets, offer researchers exceptional brightness with narrow excitation and emission profiles for precise resolution. StarBright Dyes are compatible with most experimental protocols and flow cytometers, including the Bio-Rad ZE5 Cell Analyzer, without the need for special buffers. Minimal lot-to-lot variation helps to ensure reproducible and consistent staining and the dyes are resistant to photobleaching with no loss of signal in fixation.
Immunology Research Antibodies Clinical Diagnostics Cytometry Diagnostics Flow Cytometry Life Science
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Bio-Rad Laboratories and Oncocyte Corporation Collaborate to Develop Transplant Monitoring ProductsBio-Rad Laboratories and Oncocyte Corporation have entered into a collaboration agreement to develop and commercialize transplant monitoring products using Bio-Rad's Droplet Digital PCR instruments and reagents. Bio-Rad has also committed to participate in a private placement of Oncocyte's equity and has secured exclusive commercial rights in certain markets.
Read more »
How to produce Dyes in Manor LordsAre your Tailor's Shops clamouring to jazz up their garbs with some colour? Here's how to produce Dyes in Manor Lords.
Read more »
Bio-Rad launches first ultrasensitive multiplexed digital PCR assay for breast cancer mutation detection in clinical researchBio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, today announced the launch of its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ESR1 Mutation Detection Kit.
Read more »
CN Bio raises $21 million USD in first close of Series B investment roundBayland Capital and founding shareholder, CN Innovations Holdings Ltd, to invest $10 M and $5.5 M, respectively. Investment will expand product development and scaling of the organization to meet increased demand for Organ-on-a-Chip (OOC) solutions.
Read more »
‘Bio-spaces’ exhibition at Roca London Gallery celebrates biophilic design‘Bio-Spaces: regenerative, resilient futures’ opens at the Roca London Gallery as ‘a call to action to stop designing nature out’
Read more »
Bio-Techne surpasses 10,000 peer-reviewed publications citing RNAscope technologyBio-Techne Corporation today announced that Advanced Cell Diagnostics (ACD), part of Bio-Techne's Spatial Biology Division, has surpassed 10,000 peer-reviewed publications referencing the use and application of RNAscope™ ISH technology.
Read more »